DAWNRAYS PHARMA Reports Interim Results with Net Profit Attributable to Shareholders at Approximately 105 Million Yuan, Down 78.79% Year-over-Year
Deep News
Aug 25
DAWNRAYS PHARMA (02348) announced its interim results for 2025, reporting revenue of approximately 630 million yuan, representing a year-over-year increase of 9.2%. Gross profit reached approximately 314 million yuan, marking a decline of 7.1% compared to the same period last year.
Net profit attributable to owners of the parent company totaled approximately 105 million yuan, reflecting a significant decrease of 78.79% year-over-year. Earnings per share stood at 0.06961 yuan, while the interim dividend per share was set at 0.015 Hong Kong dollars.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.